Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 7/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751531 | 0.88 | TSHR (0.43) | TSHRSMN1; SMN2HRH3 | |
| SCHEMBL27756370 | 0.80 | KDM4E (0.44) | SMN1; SMN2TRPV1 | |
| SCHEMBL3074346 | 0.78 | TRPV1 (0.39) | TRPV1CYP3A4 | |
| SCHEMBL27756383 | 0.77 | KCNH2 (0.39) | SMN1; SMN2HRH3 | |
| SCHEMBL27735748 | 0.76 | CSNK2A1 (0.40) | — | |
| SCHEMBL24592940 | 0.75 | TSHR (0.46) | TSHRSMN1; SMN2PTGESATMTRPV1 | |
| SCHEMBL3085740 | 0.75 | HTR1A (0.43) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3075600 | 0.75 | HTR1A (0.41) | TSHRSMN1; SMN2ATMCYP1A2 | |
| SCHEMBL1751077 | 0.74 | TAAR1 (0.45) | TSHRSMN1; SMN2ATMCYP1A2CYP3A4 | |
| SCHEMBL3075613 | 0.73 | HTR2C (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| CN-101379033-A | Secondary amines | ACTELION PHARMACEUTICALS LTD (CH) | 2009-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | TSHR 1994/4885SMN1; SMN2 4441/4885PTGES 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.